Merck Ends Second Alzheimer’s Trial With Neuphoria; Stocks Slide
NEUP•Merck has terminated a second Alzheimer’s drug trial under its Neuphoria collaboration, stripping the partnership of another key therapeutic candidate and raising questions about its research momentum. Neuphoria’s stock plunged sharply on the news, while Merck shares also declined, reflecting investor concern over future clinical milestones.
1. Trial Cancellation
Merck has halted another Alzheimer’s clinical study within its Neuphoria collaboration, marking the second discontinuation under the pact this year. Interim efficacy data fell short of primary endpoints, prompting an immediate stop to all dosing activities for the program.
2. Market Reaction
Neuphoria shares plunged sharply in early trading, while Merck stock dipped as investors digested the development. Trading volumes spiked as market participants reassessed the collaboration’s valuation and timelines.
3. Pipeline Implications
The cancellation further narrows the joint Alzheimer’s pipeline and delays potential regulatory milestones, intensifying pressure on Neuphoria to secure new partnerships. Both companies are expected to reallocate R&D resources toward other neuroscience initiatives with more robust efficacy data.
